Get the Stockscreener App
70.08
1.48%
1.02
After Hours:
69.71
-0.37
-0.53%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $70.08, with a volume of 5.03M.
It is up +1.48% in the last 24 hours and up +5.77% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$69.06
Open:
$69.51
24h Volume:
5.03M
Relative Volume:
0.88
Market Cap:
$217.32B
Revenue:
$51.21B
Net Income/Loss:
$6.50B
P/E Ratio:
33.61
EPS:
2.085
Net Cash Flow:
$6.76B
1W Performance:
+5.23%
1M Performance:
+5.77%
6M Performance:
-10.30%
1Y Performance:
+4.44%
1-Day Range:
$69.49
$70.32
1-Week Range:
$67.59
$70.32
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
70.08 | 217.32B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca, Daiichi’s Drug Wins Wider Use in Breast Cancer Patients - Bloomberg
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
AstraZeneca rises Monday, outperforms market - MarketWatch
2025-01-27 | AstraZeneca PLC Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your RightsAZN - PR Newswire
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
2025-01-26 | AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Asio Capital LLC - MarketBeat
Goelzer Investment Management Inc. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Encompass More Asset Management Makes New $314,000 Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Dakota Wealth Management Sells 6,806 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before - The Bakersfield Californian
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - GlobeNewswire Inc.
AstraZeneca PLC's (LON:AZN) Popularity With Investors Is Clear - Simply Wall St
AstraZeneca Canadian investment to drive R&D growth -January 24, 2025 at 12:01 pm EST - Marketscreener.com
AstraZeneca rises Friday, outperforms market - MarketWatch
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
Here's Why Astrazeneca (AZN) is a Strong Growth Stock - Yahoo Finance
AstraZeneca Sees Canada As Land Of Opportunity With $570m Investment - News & Insights
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth - Benzinga
Class Action Filed Against AstraZeneca PLC (AZN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Morningstar
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by SG Americas Securities LLC - MarketBeat
Deadline Alert: AstraZeneca PLC (AZN) Investors Who Lost - GlobeNewswire
AstraZeneca: $570 million invested in Canada -January 24, 2025 at 03:52 am EST - Marketscreener.com
AstraZeneca announces new $820 million investment in Canada - BNN Bloomberg
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office -January 23, 2025 at 03:10 pm EST - Marketscreener.com
AstraZeneca to invest $820-million in Ontario life sciences sector, says it will create 700 jobs - The Globe and Mail
AstraZeneca to invest $570M in Canada (AZN:NASDAQ) - Seeking Alpha
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery - Quantisnow
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery – Company AnnouncementFT.com - Financial Times
AstraZeneca to invest $570m in Canada, creating 700 new jobs By Investing.com - Investing.com South Africa
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating (NASDAQ:AZN) - Seeking Alpha
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
4,544 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by True North Advisors LLC - MarketBeat
Wesbanco Bank Inc. Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC Sued for Securities Law ViolationsContact The Gross Law Firm Before February 21, 2025 to Discuss Your RightsAZN - PR Newswire
2025-01-23 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AZN LAWSUIT ALERT: Levi & Korsinsky Notifies AstraZeneca - GlobeNewswire
Merit Financial Group LLC Has $579,000 Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Oral Anticoagulants Market May See a Big Move | AstraZeneca, Pfizer, Boehringer Ingelheim - openPR
Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class Action - GlobeNewswire
Why Is AstraZeneca PLC (AZN) Among the Best Large-Cap Value Stocks to Buy in 2025? - Insider Monkey
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi - Pharmaceutical Technology
AstraZeneca falls Wednesday, underperforms market - MarketWatch
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - GlobeNewswire
AstraZeneca FY2026 EPS Estimate Increased by Leerink Partnrs - MarketBeat
NICE recommends two AstraZeneca lung cancer treatments - The Pharma Letter
Chesley Taft & Associates LLC Cuts Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):